Autolus Therapeutics plc (NASDAQ:AUTL) Stake Boosted by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 618,942 shares of the company's stock after acquiring an additional 368,071 shares during the period. Renaissance Technologies LLC owned about 0.23% of Autolus Therapeutics worth $1,455,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in shares of Autolus Therapeutics by 4.6% during the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after acquiring an additional 1,125,454 shares in the last quarter. Candriam S.C.A. bought a new position in shares of Autolus Therapeutics in the fourth quarter worth about $7,500,000. JPMorgan Chase & Co. increased its position in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after buying an additional 761,008 shares during the period. BIT Capital GmbH raised its stake in Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock valued at $1,497,000 after purchasing an additional 379,050 shares during the last quarter. Finally, State Street Corp raised its position in shares of Autolus Therapeutics by 1.7% during the third quarter. State Street Corp now owns 606,544 shares of the company's stock valued at $2,202,000 after buying an additional 10,401 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Up 4.5 %

NASDAQ:AUTL opened at $1.39 on Tuesday. Autolus Therapeutics plc has a 12-month low of $1.11 and a 12-month high of $5.00. The stock's fifty day simple moving average is $1.62 and its 200-day simple moving average is $2.43. The firm has a market capitalization of $369.87 million, a P/E ratio of -1.15 and a beta of 2.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, equities research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Finally, Truist Financial dropped their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics presently has an average rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.